



FOR IMMEDIATE RELEASE

Pique Therapeutics Receives Grant Under the Qualifying Therapeutic Discovery Project Program

Durham, North Carolina – November 17, 2010 -- Pique Therapeutics, Inc., a biopharmaceutical company, announced today that it has been awarded a grant for drug development activities under the Qualified Therapeutic Discovery Project (“QTDP”) program.

The QTDP program was created by the U.S. Congress as part of the Patient Protection and Affordable Care Act of 2010. It was intended to provide incentive to smaller companies who are focusing on innovative therapeutic discoveries. QTDP grants or tax credits are awarded to companies with fewer than 250 employees for projects related to the treatment or prevention of diseases through the conduct of pre-clinical or clinical studies.

“We are delighted that Pique Therapeutics was selected to be a beneficiary of the QTDP grant,” said Christopher S. Meldrum, President of Pique Therapeutics. “This award reflects the substantial clinical promise of our lead drug for the treatment of non-small cell lung cancer, PT 107.”

About Pique Therapeutics

Pique Therapeutics is a biopharmaceutical company seeking to become the leader in the development and commercialization of new therapeutic vaccines, focused initially on the treatment of cancer. The Company was founded on the research of Eckhard R. Podack, M.D., Ph.D., who is Chair of the Department of Immunology and Microbiology at the University of Miami.

About PT 107

Pique’s lead product, PT 107, is a first-in-class therapeutic vaccine for the treatment of non-small cell lung cancer and has completed Phase 1 clinical trials, where it was well tolerated, exhibited a very good safety profile in cancer patients. PT 107 showed a dramatic improvement in median overall survival (11 months) for patients with second-line, late-stage non-small cell lung cancer, more than doubling the expected 4 to 6 months survival in these patients. Remarkably, over 30% of PT 107-treated patients survived 4 years or longer, while currently-approved treatments extend overall survival in this group of patients by approximately 2-3 months.

Contact:

Christopher S. Meldrum
President
Pique Therapeutics, Inc.
(919) 806-4395